HADHA and hepatocellular carcinoma: When cutting off with mIOD, 22.4% (30/134) of HCC patients were sorted into HADHA low-expressed group (HADHAlow) and 77.6% (104/134) were into HADHA high-expressed group (HADHAhigh).